Relbiplat 50mg Injection
Product introduction
Relbiplat 50mg Injection is given as an injection into vein by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Nausea, fatigue, vomiting, and diarrhea are some common side effects of this medicine. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. It may cause some serious allergic reaction, inform your doctor if you notice sore lips or mouth ulcers, rash, itching and difficulty breathing. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels.
Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. It makes men infertile, hence men should take doctor advice about the freezing of sperm before the treatment. You must avoid driving after taking this medicine as it may cause dizziness.
Uses of Relbiplat Powder for Injection
Side effects of Relbiplat Powder for Injection
Common side effects of Relbiplat
- Abdominal pain
- Injection site reaction
- Weight gain
- Conjunctivitis
- Fever
- Nosebleeds
- Hair loss
- Constipation
- Skin disorder
- Decreased appetite
- Infection
- Peripheral sensory neuropathy
- Inflammation of the nose
- Pain
- Increased transaminase level in blood
- Increased alkaline phosphatase level in blood
- Taste change
- Edema (swelling)
- Lacrimation disorder
- Allergic reaction
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Stomatitis (Inflammation of the mouth)
- Anemia (low number of red blood cells)
- Decreased white blood cell count (neutrophils)
- Low blood platelets
- Headache
- Breathlessness
How to use Relbiplat Powder for Injection
How Relbiplat Powder for Injection works
Safety advice
Relbiplat 50mg Injection treatment may result in an increased risk of dizziness, nausea, and vomiting, and other neurological symptoms that affect walking and this may affect your ability to drive.
Limited information is available on the use of Relbiplat 50mg Injection in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
What if you forget to take Relbiplat Powder for Injection?
All substitutes
Quick tips
- Relbiplat 50mg Injection is given as an injection into veins under the supervision of a doctor.
- Relbiplat 50mg Injection is given as an injection into veins under the supervision of a doctor.
Fact Box
Patient concerns
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Bertino J, Cleary J, et al. Cytotoxic Agents. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1689-90.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 944.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1034-35.
- Oxaliplatin. Hayes, UK: Ranbaxy (UK) Limited a Sun Pharmaceutical Company; 2011 [19 Apr. 2018]. [Accessed 22 Jan. 2019] (online) Available from:
- Oxaliplatin. Bridgewater, New Jersey: sanofi-aventis U.S; 2002 [revised Oct. 2015]. [Accessed 26 Mar. 2019] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). [Accessed 26 Mar. 2019] (online) Available from:
Marketer details
Lab tests offered by us
